Prudentia Sciences provides an artificial-intelligence platform that enables pharmaceutical companies, biotechs, and financial institutions to evaluate breakthrough medicines with greater speed and rigor. The system synthesizes complex clinical signals into actionable insights and uses a human-in-the-loop workflow to facilitate secure, compliant collaboration among buyers, sellers, and intermediaries. Operating as a single, continuously updated source of truth, the platform helps teams make high-stakes acquisition, licensing, and investment decisions more confidently and in a fraction of the traditional time. Its explainable AI and intelligent automation modernize a traditionally fragmented diligence process. With fresh capital in hand, the company plans to expand product capabilities, deepen both technical and non-technical intelligence, and scale commercial operations. Geographic expansion to the Asia-Pacific and Europe is also on the roadmap. Headquartered in Cambridge, Massachusetts, Prudentia has raised $27 million to date, including a $7 million seed round completed in 2024.

Total raised

$27M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2026